Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products
New York, Basel, and Fargo, N.D., June 16, 2021 – Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and...
Aruvant Announces ARU-2801 Data Publications and Advocacy Partnership
--ARU-2801 is a potentially curative gene therapy in development for individuals with hypophosphatasia (HPP)----Data published in Molecular Therapy: Methods & Clinical Development showed improved survival out to 18 months in HPP mice----Aruvant has signed...
Aruvant Announces Oral Presentation at 15th Annual Sickle Cell Disease Research & Educational Symposium & 44th National Sickle Cell Disease Scientific Meeting
--Data demonstrates promise for lead program, ARU-1801, as potentially curative treatment for sickle cell disease-- New York, NY, and BASEL, Switzerland, May 27, 2021 – Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for...
Aruvant Announces Data Presentation on Lead Program ARU-1801 at European Hematology Association (EHA) 2021 Virtual Congress
--Data suggest individualized melphalan dosing prior to ARU-1801 infusion may improve patient outcomes-- NEW YORK and BASEL, Switzerland, May 12, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies...
Aruvant’s Eleven New Hires Advance its Internal-External Supply Model Strategy to Manufacture Gene Therapies for Rare Diseases
NEW YORK and BASEL, Switzerland, May 4, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in...
Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting
--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease-- NEW YORK and BASEL, Switzerland, Apr. 27, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on...
Aruvant Appoints Meghan Kelton Executive Director of Human Resources and E. Blair Clark-Schoeb Senior Vice President of Communications
NEW YORK and BASEL, Switzerland, Apr. 23, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive...
Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March
NEW YORK and BASEL, Switzerland, Feb. 11, 2021 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple...